Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem - PubMed
- ️Thu Jan 01 2009
Clinical Trial
. 2009 Aug 1;49(3):395-401.
doi: 10.1086/600295.
Sung-Han Kim, Kye Hyoung Kim, Choong Jong Kim, Shinwon Lee, Kyoung-Ho Song, Jae Hyun Jeon, Wan Beom Park, Hong Bin Kim, Sang-Won Park, Nam Joong Kim, Eui-Chong Kim, Myoung-Don Oh, Kang Won Choe
Affiliations
- PMID: 19569970
- DOI: 10.1086/600295
Clinical Trial
Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem
Hee-Chang Jang et al. Clin Infect Dis. 2009.
Abstract
Background: Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high mortality rates, but no treatment strategy has yet been established. We performed this study to evaluate the efficacy of linezolid with or without carbapenem in salvage treatment for persistent MRSA bacteremia.
Methods: All adult patients with persistent MRSA bacteremia for 7 days from January 2006 through March 2008 who were treated at Seoul National University Hospital were studied. The results of linezolid salvage therapy with or without carbapenem were compared with those of salvage therapy with vancomycin plus aminoglycosides or rifampicin.
Results: Thirty-five patients with persistent MRSA bacteremia were studied. The early microbiological response (ie, negative results for follow-up blood culture within 72 hours) was significantly higher in the linezolid-based salvage therapy group than the comparison group (75% vs 17%; P =.006). Adding aminoglycosides or rifampicin to vancomycin was not successful in treating any of the patients, whereas linezolid-based therapy gave an 88% salvage success rate P =.001). The S. aureus-related mortality rate was lower for patients treated with a linezolid salvage regimen than for patients continually treated with a vancomycin-based regimen (13% vs 53%; P =.030).
Conclusions: Linezolid-based salvage therapy effectively eradicated S. aureus from the blood for patients with persistent MRSA bacteremia. The salvage success rate was higher for linezolid therapy than for vancomycin-based combination therapy.
Comment in
-
Tattevin P, Uhel F, Fily F. Tattevin P, et al. Clin Infect Dis. 2009 Dec 15;49(12):1960; author reply 1961. doi: 10.1086/648500. Clin Infect Dis. 2009. PMID: 19929392 No abstract available.
Similar articles
-
Park HJ, Kim SH, Kim MJ, Lee YM, Park SY, Moon SM, Park KH, Chong YP, Lee SO, Choi SH, Woo JH, Kim YS. Park HJ, et al. J Infect. 2012 Dec;65(6):505-12. doi: 10.1016/j.jinf.2012.08.007. Epub 2012 Aug 14. J Infect. 2012. PMID: 22902942 Clinical Trial.
-
Vernadakis S, Saner FH, Rath PM, Kaiser GM, Mathe Z, Treckmann J, Paul A. Vernadakis S, et al. Transpl Infect Dis. 2009 Aug;11(4):346-8. doi: 10.1111/j.1399-3062.2009.00403.x. Epub 2009 May 21. Transpl Infect Dis. 2009. PMID: 19497075
-
Shorr AF, Kunkel MJ, Kollef M. Shorr AF, et al. J Antimicrob Chemother. 2005 Nov;56(5):923-9. doi: 10.1093/jac/dki355. Epub 2005 Sep 29. J Antimicrob Chemother. 2005. PMID: 16195255
-
[Lipopeptides and oxazolidinones--novel antibiotics in MRSA infection treatment].
Pangercić A, Bukovski-Simonoski S, Barsić B. Pangercić A, et al. Lijec Vjesn. 2010;132 Suppl 1:11-3. Lijec Vjesn. 2010. PMID: 20715711 Review. Croatian.
Cited by
-
Kang CK, Kwak YG, Park Y, Song KH, Kim ES, Jung SI, Park KH, Park WB, Kim NJ, Kim YK, Jang HC, Lee S, Jeon JH, Kwon KT, Kim CJ, Kim YS, Kim HB; Korea INfectious Diseases (KIND) study group. Kang CK, et al. Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1119-1123. doi: 10.1007/s10096-018-3226-6. Epub 2018 Apr 17. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29667110
-
Song KH, Kim ES, Sin HY, Park KH, Jung SI, Yoon N, Kim DM, Lee CS, Jang HC, Park Y, Lee KS, Kwak YG, Lee JH, Park SY, Song M, Park SK, Lee YS, Kim HB; Korea INfectious Diseases (KIND) study group. Song KH, et al. BMC Infect Dis. 2013 Dec 10;13:581. doi: 10.1186/1471-2334-13-581. BMC Infect Dis. 2013. PMID: 24321206 Free PMC article.
-
Kim NH, Sung JY, Choi YJ, Choi SJ, Ahn S, Ji E, Kim M, Kim CJ, Song KH, Choe PG, Park WB, Kim ES, Park KU, Kim NJ, Oh MD, Kim HB. Kim NH, et al. BMC Infect Dis. 2020 Nov 30;20(1):901. doi: 10.1186/s12879-020-05641-z. BMC Infect Dis. 2020. PMID: 33256638 Free PMC article.
-
Park KH, Shin JH, Lee SY, Kim SH, Jang MO, Kang SJ, Jung SI, Chung EK, Ko KS, Jang HC. Park KH, et al. PLoS One. 2013 Jun 3;8(6):e65026. doi: 10.1371/journal.pone.0065026. Print 2014. PLoS One. 2013. PMID: 23755171 Free PMC article.
-
Baxi SM, Clemenzi-Allen A, Gahbauer A, Deck D, Imp B, Vittinghoff E, Chambers HF, Doernberg S. Baxi SM, et al. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5276-84. doi: 10.1128/AAC.00658-16. Print 2016 Sep. Antimicrob Agents Chemother. 2016. PMID: 27324762 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical